Related Experiment Video
Updated: Oct 1, 2025
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Inhibitors of PARP: Number crunching and structure gazing
Johannes Rudolph1, Karen Jung1, Karolin Luger1,2
1Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80309.
Abstract:
SignificancePARP is an important target in the treatment of cancers, particularly in patients with breast, ovarian, or prostate cancer that have compromised homologous recombination repair (i.e., BRCA-/-). This review about inhibitors of PARP (PARPi) is for readers interested in the development of next-generation drugs for the treatment of cancer, providing insights into structure-activity relationships, in vitro vs. in vivo potency, PARP trapping, and synthetic lethality.
Insights
Poly (ADP-ribose) polymerase inhibitors (PARPi) are crucial for treating cancers with DNA repair defects, such as BRCA mutations. This review explores next-generation PARPi development, focusing on structure-activity, potency, and synthetic lethality.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Poly (ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair pathways.
- Defects in homologous recombination repair (e.g., BRCA mutations) sensitize cancer cells to PARP inhibition.
- PARP inhibitors (PARPi) represent a significant therapeutic strategy in oncology.
Purpose of the Study:
- To provide an overview of next-generation PARP inhibitors (PARPi).
- To discuss structure-activity relationships (SAR) of PARPi.
- To explore concepts like in vitro vs. in vivo potency, PARP trapping, and synthetic lethality in the context of PARPi.
Main Methods:
- Literature review of scientific publications on PARP inhibitors.
- Analysis of structure-activity relationships for various PARPi.
- Discussion of preclinical and clinical data regarding PARPi efficacy and mechanisms.
Main Results:
- PARPi efficacy is strongly linked to homologous recombination deficiency (HRD).
- PARP trapping is an emerging mechanism of action for potent PARPi.
- Next-generation PARPi aim to overcome resistance and broaden therapeutic applications.
Conclusions:
- PARPi are effective in cancers with HRD, including breast, ovarian, and prostate cancers.
- Understanding SAR, potency, and novel mechanisms like PARP trapping is vital for developing improved PARPi.
- PARPi hold significant promise for future cancer treatment strategies, particularly in combination therapies.
